New York, NY, Las Vegas, NV, Tokyo, JP, July 23, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. ("Instinct Bio," "BIOT," or the "Company"), the parent company of Instinct Bio ...

Add Yahoo as a preferred source to see more of our stories on Google. A cross-section of a bristle worm jaw sample with the indentation testing sites labeled 1 to 11. (CREDIT: Zelaya-Lainez et al.) ...

Novartis NOVN-1.77%decrease; down pointing triangle said it agreed to pay up to $1.5 billion for Myricx Bio, in a bid to bolster its portfolio amid industry competition for oncology drugs. The Swiss ...

Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell therapy gives ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...

The fifth chapter of Deltarune, the indie RPG from Undertale creator Toby Fox, is finally out. This brings the story one step closer to the conclusion of the episodic game that released its first ...

Deltarune Chapter 5 arrives Wednesday at 11:00 AM ET as a free update for everyone who already owns the $24.99 indie RPG — and the accompanying newsletter from developer Toby Fox contains a disclosure ...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on ...

Scott Baird is a Contributor at DualShockers with over a decade of experience writing about video games, board games, and tabletop RPGs. He has been writing professionally since 2013 and covering ...

Johnson & Johnson JNJ0.88%increase; up pointing triangle has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker’s oncology pipeline. J&J on ...